PMID- 31145316
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 22
DP  - 2019 May
TI  - Safety of aripiprazole for tics in children and adolescents: A systematic review 
      and meta-analysis.
PG  - e15816
LID - 10.1097/MD.0000000000015816 [doi]
LID - e15816
AB  - BACKGROUND: Aripiprazole is widely used in the management of tic disorders (TDs), 
      we aimed to assess the safety of aripiprazole for TDs in children and 
      adolescents. METHODS: A systematic literature review was performed in the 
      databases of MEDLINE, Embase, the Cochrane Library and 4 Chinese databases, from 
      inception to February 2019. All types of studies evaluating the safety of 
      aripiprazole for TDs were included. The quality of studies was assessed using the 
      Cochrane Risk of Bias tool, the Newcastle-Ottawa Scale tool, the National 
      Institute of Clinical Excellence, the CARE (Case Report) guidelines according to 
      types of studies. Risk ratio (RR) and incidence rate with a 95% confidence 
      interval (CI) were used to summarize the results. RESULTS: A total 50 studies 
      involving 2604 children met the inclusion criteria. The result of meta-analysis 
      of randomized controlled trials showed that there was a significant difference 
      between aripiprazole and haloperidol with respect to rate of somnolence 
      (RR = 0.596, 95% CI: 0.394, 0.901), extrapyramidal symptoms (RR = 0.236, 95% CI: 
      0.111, 0.505), tremor (RR = 0.255, 95% CI: 0.114, 0.571), constipation 
      (RR = 0.148, 95% CI: 0.040, 0.553), and dry mouth (RR = 0.141, 95% CI: 0.046, 
      0.425). There was a significant difference between aripiprazole and placebo in 
      the incidence rate of adverse events (AEs) for somnolence (RR = 6.565, 95% CI: 
      1.270, 33.945). The meta-analysis of incidence of AEs related to aripiprazole for 
      case series studies revealed that the incidence of sedation was 26.9% (95% CI: 
      16.3%, 44.4%), irritability 25% (95% CI: 9.4%, 66.6%), restlessness 31.3% (95% 
      CI: 13%, 75.1%), nausea and vomiting 28.9% (95% CI: 21.1%, 39.5%), and weight 
      gain 31.3% (95% CI: 10.7%, 91.3%). CONCLUSION: Aripiprazole was generally well 
      tolerated in children and adolescents. Common AEs were somnolence, headache, 
      sedation, nausea, and vomiting. Further high-quality studies are needed to 
      confirm the safety of aripiprazole for children and adolescents with TDs.
FAU - Yang, Chunsong
AU  - Yang C
AD  - Department of Pharmacy, Evidence-based Pharmacy Center, West China Second 
      Hospital, Sichuan University.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children 
      (Sichuan University), Ministry of Education.
FAU - Yi, Qiusha
AU  - Yi Q
AD  - Department of Pharmacy, Evidence-based Pharmacy Center, West China Second 
      Hospital, Sichuan University.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children 
      (Sichuan University), Ministry of Education.
AD  - West China School of Medicine.
FAU - Zhang, Lingli
AU  - Zhang L
AD  - Department of Pharmacy, Evidence-based Pharmacy Center, West China Second 
      Hospital, Sichuan University.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children 
      (Sichuan University), Ministry of Education.
FAU - Cui, Hao
AU  - Cui H
AD  - Department of Pediatric Neurology, West China Hospital, Sichuan University, 
      Chengdu.
AD  - Department of Health, Zhuhai Maternity and Child Health Hospital, Zhuhai, 
      Guangdong, China.
FAU - Mao, Jianping
AU  - Mao J
AD  - West China School of Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antipsychotic Agents)
RN  - 82VFR53I78 (Aripiprazole)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Adolescent
MH  - Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Aripiprazole/administration & dosage/adverse effects/*therapeutic use
MH  - Child
MH  - Haloperidol/therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Tic Disorders/*drug therapy
PMC - PMC6709053
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/05/31 06:00
MHDA- 2019/06/14 06:00
PMCR- 2019/05/31
CRDT- 2019/05/31 06:00
PHST- 2019/05/31 06:00 [entrez]
PHST- 2019/05/31 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2019/05/31 00:00 [pmc-release]
AID - 00005792-201905310-00046 [pii]
AID - MD-D-18-06236 [pii]
AID - 10.1097/MD.0000000000015816 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 May;98(22):e15816. doi: 10.1097/MD.0000000000015816.